Telix Pharmaceuticals announced a new independent analysis of its Phase 3 ZIRCON trial data, published in European Urology, demonstrating that TLX250-Px (Zircaix®) PET/CT imaging is highly predictive of renal malignancies across all subtypes, including non-clear cell renal cell carcinoma (nccRCC). The study showed a 98% positive predictive value, 82% sensitivity, and 87% specificity, suggesting TLX250-Px could improve diagnosis and management of kidney cancers beyond just clear cell RCC. This expands the potential clinical use of TLX250-Px, which was originally developed for clear cell RCC detection. Further evaluation is anticipated to confirm its broader application in renal cancer care.
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
Catalyst Acquisition Corp. announced the pricing of its initial public offering (IPO) at $10 per unit, raising $200 million by offering 20 million units. The units, each including one Class A ordinary share and a partial share right, will begin tradi...
Elevra Lithium reported a strong June quarter with North American Lithium achieving its second-best quarterly production and a new monthly record in May. The company improved plant recoveries and maintained high mill utilization. Strategically, Elevr...
The US dollar index surged to a 13-month high driven by growing speculation of a Federal Reserve rate hike amid persistent inflation and high energy prices. This strengthened dollar has pressured Bitcoin and Ethereum, which typically move inversely t...
